Oneview Healthcare (ASX:ONE): Health-Technology Growth in Focus

Aditi Sarkar

30 July 2026 09:37 PM AEST

Oneview Healthcare (ASX:ONE): Health-Technology Growth in Focus

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Oneview Healthcare Plc (ASX:ONE) topped the All Ordinaries on 30 July 2026, closing at 17 cents on a falling market.
Oneview Healthcare Plc (ASX:ONE) was the standout performer on Australia's small-cap health-technology bench on Thursday, 30 July 2026, closing at 17 cents to sit atop the All Ordinaries leaderboard on a day the broader market fell.
The move stood out because the wider index was in retreat: the S&P/ASX 200 moved, and the All Ordinaries movedas gold miners were sold off and money rotated toward technology names.
For a company whose shares had drifted below 15 cents in the preceding sessions, a double-digit percentage jump was always going to draw attention.

Oneview Healthcare Plc (ASX:ONE) topped the All Ordinaries on 30 July 2026, closing at 17 cents on a falling market. But with no signed Epic Bedside Hub contract yet, how much of the move is real?

Company Overview

Several developments could shape sentiment. The clearest potential catalyst would be the first signed Bedside Hub contract, which would validate the Epic-linked channel and give the market a concrete revenue marker. Progress converting the Baxter purchasing arrangement into live deployments across a large US network is another. The company has flagged half-year results on 27 August 2026 and attendance at Epic's user group meeting in mid-August, either of which could…

Recent Developments

Oneview Healthcare Plc (ASX:ONE) was the standout performer on Australia's small-cap health-technology bench on Thursday, 30 July 2026, closing at 17 cents to sit atop the All Ordinaries leaderboard on a day the broader market fell. The move stood out because the wider index was in retreat: the S&P/ASX 200 moved, and the All Ordinaries movedas gold miners were sold off and money rotated toward technology…

Financial and Operational Snapshot

For the year to 31 December 2025, Oneview reported revenue of €12.0 million, up 21%, with recurring revenue of €7.7 million (up 7%) and a sharp 60% jump in hardware and services income. The Irish-domiciled company reports in euros and carries a 31 December balance date, a quirk Australian investors need to keep in mind when comparing figures. Full-year customer receipts were about €12.6 million.

What May Be Watched Next

Key Risks

The risks are equally clear. Oneview remains loss-making and cash-hungry: quarterly operating outflow of €2.9 million against €7.2 million of cash underscores a limited runway without the second placement tranche, which requires shareholder approval later in 2026. That reliance on fresh equity points to ongoing dilution risk, and the stock is already trading below its 19-cent placement price.

What does Oneview Healthcare do?

What is the latest development?

What financial or operational point stands out?

What may be watched next?

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.